Rigel
corporate overview

pipeline

investors & media

careers



 press release archive

press release archive

Current | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997


12/11/2003 Rigel's R112 for Allergic Rhinitis Achieves Positive Safety Profile
11/12/2003 Rigel Initiates Clinical Trial in Hepatitis C
11/10/2003 Rigel Pharmaceuticals to Present at CIBC World Markets' Fourteenth Annual Healthcare Conference
11/6/2003 Rigel to Host Hepatitis C Investor Briefing on November 19, 2003
11/5/2003 Rigel Announces Third Quarter 2003 Financial Results
11/3/2003 Rigel Secures Hepatitis C Virus License Agreement from Chiron Corporation
10/31/2003 Rigel Pharmaceuticals to Present at 2003 Credit Suisse First Boston Healthcare Conference
10/27/2003 Data Presented at American College of Rheumatology Shows Significant Reduction in Severity of Experimental Arthritis
10/20/2003 Discovery of Peptides with Anti-Proliferative Effects
10/16/2003 Rigel Pharmaceuticals to Present at Rodman & Renshaw Techvest Healthcare Conference
10/7/2003 Rigel Pharmaceuticals Appoints Robin Cooper, Ph.D., D.Sc., Senior Vice President of Pharmaceutical Sciences
9/18/2003 Rigel Pharmaceuticals to Present at UBS Warburg Conference on September 22
9/14/2003 Rigel Team Discovers New Regulators of the Immune System
9/10/2003 Rigel Initiates Multi-Dose Safety Trial of R112 for Allergic Rhinitis
8/5/2003 Rigel Announces Second Quarter 2003 Financial Results
8/1/2003 Rigel Completes Stockholder Rights Offering
7/20/2003 Rigel Completes Clinical Trial of R112 in Allergic Rhinitis
6/30/2003 Rigel Commences Stockholder Rights Offering
6/27/2003 Rigel Closes $46 Million in Financing
6/24/2003 Rigel Announces 1 for 9 Reverse Stock Split
6/20/2003 Rigel Pharmaceuticals' Stockholders Approve Financing and Other Related Proposals at Annual Stockholders’ Meeting
5/30/2003 Rigel to Present at Needham Second Annual Biotechnology Conference on June 6, 2003
5/30/2003 Rigel to Present at Euro-Biotech Conference on June 3, 2003
5/30/2003 Rigel to Present at White Mountain Capital Biotechnology Conference on June 5, 2003
5/6/2003 Rigel Announces First Quarter 2003 Financial Results
4/30/2003 Rigel Signs Definitive Agreement for $46 Million Financing to Support Clinical Product Candidates
4/2/2003 Rigel Receives Second Milestone Payment From Daiichi for Progress In Developing Novel Cancer Drug
3/21/2003 Rigel Pharmaceuticals Presents Drug Discovery Programs in Oncology At Two Symposia
3/5/2003 Rigel Pharmaceuticals Presents Drug Development Programs in Oncology and Allergy/Inflammation at the Protein Phosphorylation Drug Discovery World Summit
2/24/2003 Rigel to Present at BIO CEO & Investor Conference 2003
2/5/2003 Rigel Announces 2002 Fiscal Year Financial Results
1/31/2003 Rigel Announces Restructuring To Reduce Spending
1/13/2003 Rigel Begins U.S. Clinical Testing Of Allergy Drug
1/7/2003 Rigel Receives Milestone Payment from Daiichi in Cancer Drug Deal
© 2013 Rigel  |  privacy  |  disclaimer | Follow Us On:    contact us  |  site map  |  search    Search